SEATTLE, Wash and VANCOUVER, British Columbia, September 10, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that cytisinicline data will be featured in two presentations on Friday, September 18th, at the SRNT-E virtual conference. Both presentations evaluate…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, September 3, 2020 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will present at two upcoming investor conferences. H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16th…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, August 6, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2020 financial results and provided an update on the cytisinicline clinical development program. Recent Highlights Announced…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, August 4, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 476,187 shares of its common stock at a price to…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, August 3. 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock…
/Read More